Background: Primary chemotherapy has been tested as a possible approach for patients with high risk features but predicted clear mesorectal margins on preoperative MRI assessment. This study investigates the prognostic relevance of baseline and post-treatment MRI and pathology staging in rectal cancer patients undergoing primary chemotherapy.
Introduction
High resolution pelvic magnetic resonance imaging (MRI) is a validated preoperative staging tool for rectal cancer [1] . Many centres offer preoperative chemo-radiotherapy (CRT) locally advanced, T3, T4 rectal adenocarcinoma and tumours threatening the potential resection planes. CRT converts 74% (60/81) of rectal cancer patients with a positive circumferential margin (CRM) at baseline to negative CRM post-treatment [2] . This results in a reduction in local recurrence, with a relative risk reduction of local recurrence in favour of MRI-CRM downstaging by preoperative therapy of 0.30 (95% CI: 0.12-0.74; P ¼ 0.009) [2] . Furthermore, good prognosis tumours (MRI-predicted safe CRM, with MRI-predicted T2/T3a/T3b) were accurately identified preoperatively and with good quality total mesorectal excision (TME) surgery, the local and distance relapse rates at 5 years were 3% and 20%, respectively [3] . On the other hand, 30-40% of rectal cancer patients have baseline MRI EMVI positivity which confers a significantly higher risk of recurrence. Smith et al.'s data shows a 3-year relapse-free survival rates of 71% for EMVI negative patients, versus 32% for EMVI positive patients (P¼ 0.0015) [4] . Therefore it is possible that patients with MRI identified risk factors for recurrence could benefit from systemic treatment. A high rate of response to systemic induction chemotherapy, prior to CRT and TME has previously been shown [5] . Furthermore, histology of rectal cancer patients' post-neoadjuvant chemotherapy for synchronous liver metastasis has shown complete/predominant fibrosis in 1/3 of primaries [6] .
A pilot study by Schrag et al. [7] enrolled 32 patients with clinically staged II and III rectal cancer and candidates for low anterior resection with TME. Patients received six cycles of FOLFOX, with Bevacizumab included for cycles 1-4. Patients with clinically stable/progressive disease underwent radiation before TME, whereas clinical responders had TME. All 32 patients had R0 resections. Of 30 patients completing preoperative chemotherapy, all had tumour regression and TME. The 4-year local recurrence rate was 0%; the 4-year disease-free survival (DFS) was 84%. The PROSPECT study will further investigate these results (ClinicalTrials.gov Identifier:NCT01515787).
These observations suggest that preoperative systemic treatment alone may be an effective local treatment that allows early treatment of micrometastases and an attractive strategy that should be tested in a population of patients (MRI-T3, clearCRM) where risk of metastatic disease predominates over local recurrence risk. In 2009, a prospective multi-centrephase II trial (GrupoEspañolMultidisciplinar en C ancerDigestivoGEMCAD0801) was undertaken to evaluate safety and efficacy of neoadjuvant Capecitabine, Oxaliplatin and Bevacizumab (CAPOX) in patients with T3, CRM clear, rectal adenocarcinoma selected by MRI. Primary results were reported in 2014 [8] , we now report a planned analysis of pre and posttreatment MRI scans. The aim is to determine the prognostic significance of MRI and pathology findings in patients undergoing primary chemotherapy in rectal cancer.
Methods-patients
This open-label, non-comparative, phase II trial prospective study was designed in accordance with Good Clinical Practice guidelines by the GEMCAD group (NCT00909987). Institutional review board approval was granted, informed consent was obtained from all patients. Twelve Spanish centres enrolled patients between July 2009 and May 2011.
About 46 patients underwent combination neoadjuvant chemotherapy prior to surgery. Forty patients had evaluable post-chemotherapy MRI and 44 had final pathology (flowchart in Figure 1 ).
Eligibility
Inclusion criteria. Biopsy proven rectal adenocarcinoma and candidate for R0 TME surgery, prior to the administration of any therapy. Baseline MR with distal edge of tumour > 5 cm from anal verge, T3 and tumour 2 mm from mesorectal fascia.
Exclusion criteria. Metastatic disease, low tumours judged to require abdomino-perineal resection. Previous chemotherapy for colorectal cancer. Incomplete recovery from previous surgery.
Treatment
Neoadjuvantchemotherapy: Bevacizumab (7.5 mg/kg) by intravenous infusion and 130 mg/m 2 Oxaliplatin administered over 2 h; treatment was administered for four cycles (12 weeks), bevacizumab was not included in cycle 4. Re-staging MRI was performed in the third week after chemotherapy completion. When restaging MRI showed response/stable disease there was a 3-to 4-week interval between completion of chemotherapy and surgery. Those with progressive disease on restaging were referred for preoperative chemoradiation (see below).
Methods-materials and methods
MRI technique (supplementary methods, available at Annals of Oncology online). MRI tumour regression grading (mrTRG) and Modified RECIST.
mrTRG is based on the degree of tumour replacement by fibrosis and modified RECIST was documented (supplementary Table S2 , available at Annals of Oncology online).
Standardization
Worskhops were held to standardize MRI technique and ensured case report form items (baseline T stage, N stage and CRM) were accurately recorded. The central reviewer prospectively evaluated the parameters of baseline EMVI and post-treatment T, N, EMVI and mrTRG. Interobserver agreement was calculated between central radiologist (G.B.) and local radiologist (J.R.A), both with > 10 years experience in gastrointestinal imaging for baseline T stage and length/modified RECIST analysis. Inter-observer agreement was also calculated between central radiologist (G.B.) and local radiologists (J.S. and J.R.A.) for baseline mrEMVI and mrTRG. For both mrEMVI and mrTRG, agreement was defined as central review agreement with either J.S. or J.R.A.'s assessment. Kappa calculation was undertaken for the first 28 patients enrolled as per the twostage trial design described in 'Statistics' section.
Eligibility of patients was determined by the local centre radiologist. Real-time central radiology review ensured correct selection.
Chemoradiotherapy (CRT). CRT was planned before surgery for patients with progressive disease on post-chemotherapy restaging MRI. Surgery TME plane surgery was performed according to a standardized technique. The final operation choice (abdominoperineal surgery or anterior resection) was at the surgeon's discretion.
Adjuvant chemotherapy and radiotherapy. After recovering from surgery, patients were evaluated by their oncologist for consideration of postoperative chemotherapy. The regimen was at the oncologist's discretion, with four additional cycles of CAPOX recommended. Adjuvant radiotherapy was offered to patients with tumour involvement of the pCRM (R1 or R2 resection) or N2 nodal metastasis.
Histopathology
The specimen was axially sectioned into 3-5 mm slices, as described by Quirke et al. [9] . Each local centre Gastrointestinal Pathologist evaluated specimens for the post-treatment T and N stage (ypT, ypN) and EMVI (ypEMVI). Range of experience in gastrointestinal pathology was 5-20 years.
Tumour regression grading (pTRG) was evaluated according to Dworak et al. [10] . Pathological complete response (pCR) was defined as the absence of viable tumour cells in the primary tumour and lymph nodes (ypT0N0).
Follow-up
Trial follow-up comprised outpatient assessment every 3 months for 2 years and then 6 monthly. Follow-up comprised physical examination, routine blood tests and yearly CT of the thorax, abdomen and pelvis. Surgical data, date of operation and procedure performed were recorded prospectively. Date of enrolment, last follow-up and date of disease progression were also collected.
Data analysis
Tumours were categorized into 'favourable' and 'unfavourable' responders to enable binary comparison by multivariate analysis.
Based on known histological outcomes [11] 'favourable' mrT was defined as stages T3a and b with 'unfavourable' defined as T3c,T3d and T4. Based on previous study [12] , 'favourable' ymrT and ypT stages were defined as stages T0, T1, T2 and T3a with 'unfavourable' defined as mrT, ymrT and ypT stages T3b, T3c, T3d or T4. Pathological Stage T3a and T2 tumours have similar outcomes and therefore classified as 'favourable' [11] . T downstaging was designated when the ypT stage was lower than the baseline MRI T stage.
For the purpose of analysis, 'Favourable' mrN, ymrN and ypN were defined as N0, while node positivity was unfavourable. 'Favourable' mrEMVI, ymrEMVI and ypEMVI were defined as EMVI negative, while EMVI positivity was unfavourable. MR-EMVI down-staging was defined as a change in mrEMVI status from EMVI positive on baseline MRI becoming EMVI negative on post-chemotherapy MRI.
Favourable mrTRG was defined as grades 1 and 2 with unfavourable defined as stages 3, 4 and 5 [13] . Similarly favourable pathological TRG was defined as Dworak 3 and 4, while unfavourable pathological TRG was defined as Dworak 0, 1 and 2. 
Statistics
A two-stage design, as proposed by Simon, [14] was used to allow early termination if the overall response rate was <40%. The first stage enrolled 28 patients. If 12 patients responded, the treatment was continued to stage 2. With 41 patients (type I error a ¼ 0.1 and type II error b ¼ 0.1, 90% power), if 21 patients achieved CR or PR, the treatment would be considered suitable for further evaluation. The planned patient number was increased to 46 to allow for a 10% drop-out rate.
DFS was measured from date of enrolment until progression at any site (local and/or distant), second tumour or death from any cause, whichever happened first. Patients who were alive and disease free were censored at last follow-up. Cumulative incidence of recurrence was measured from enrolment date until progression at any site (local and/or distant). All other events were censored at last follow-up.
Cox-proportional hazard models analysed the effect on DFS and cumulative incidence of recurrence by baseline MRI staging variables (mrT, mrN and mrEMVI), post-chemotherapy MRI re-staging variables (ymrT, ymrN, ymrEMVI, ymrTRG, modified mrRECIST and mrEMVI status change) and pathological variables (ypT, ypN, ypEMVI, pTRG, T downstaging and adjuvant chemotherapy).
A 3-year survival was calculated for each variable using the KaplanMeier product limit method with univariate log-rank analysis testing for differences in survival rates.
Central reviewer data was used for analysis; kappa calculation determined agreement between the two radiologists (j ¼ 0-0.20, poor agreement; j ¼ 0.21-0.40, fair agreement; j ¼ 0.41-0.60, moderate Figure 3 . Three-year DFS by T downstaging.
agreement; j ¼ 0.61-0.80, substantial agreement and j ¼ 0.81-1.00, almost perfect agreement). SPSS was used for calculations.P values of <0.05 were considered significant. Table 1 shows demographic characteristics of the 46 patients enrolled. As of November 2015, patients had been followed for a median of 41 months (range: 39-45 months). About 44 of 46 patients had evaluable post-operative pathology and complete follow-up data (two patients died during chemotherapy). No patients were referred for preoperative chemoradiation.
Results
The quality of the rectal specimen [15] was good/moderate in 43 patients and incomplete in 1. The median node harvest was 13. The CRM was involved in 2 of 44 patients who underwent surgery (4.5%), 1 due to tumour spread and 1 due to nodal disease. R0 resection was achieved in all patients. Five patients underwent adjuvant radiotherapy.
During follow-up 5 patients died, 11 patients experienced relapse (8 distant, 2 local and 1 both). The 41-month disease-free survival rate was 61% (95% CI: 46-74%), and the relapse free survival rate was 76% (95% CI: 62-86%). Following chemotherapy, ymrT, ymrEMVI, mrEMVI status change and mrTRG were significant for DFS on univariate analysis (Table 3 ). The hazard ratio for those with mrEMVI status change versus those who were MRI-EMVI negative throughout treatment was 12.2 (95% CI: 1.3-112.6).
Three-year disease-free survival (DFS)
Of the histopathology factors, T downstaging (difference between final ypT versus baseline mrT) and ypN were significant for DFS on univariate analysis (Table 4 ). Survival curves for T downstaging are illustrated in Figure 3 . However, only assessment of ypT downstaging with baseline MR T stage was significant for DFS. The hazard ratio for those with no T downstaging versus those patients with T downstaging was 14.0 (95% CI: 1.5-132.5). Tables 5-7 summarize the results of univariate and multivariate analysis of MRI and pathology variables and 3-year cumulative incidence of recurrence.
Cumulative incidence of recurrence
Of the baseline MRI factors, mrEMVI, mrT and mrN held univariate significant for cumulative incidence of recurrence (Table 5) . No factors were significant on multivariate analysisthis is likely due to significant relationships between variables shown in supplementary Tables S3-S9, available at Annals of Oncology online.
Post-chemotherapy MRI factors: ymrT, ymrEMVI, mrEMVI status change and mrTRG were significant for DFS on univariate analysis (Table 6 ). The hazard ratio for those with mrEMVI status change versus those patients who had been MRI-EMVI negative throughout treatment was 16.16 (95% CI: 1.04, 250.80), P ¼ 0.047. T downstaging was significant for cumulative incidence of recurrence, the hazard ratio for those with no T downstaging versus those patients with T downstaging was 38.65 (95% CI: 1.677-890.516) ( Table 7) .
Inter-observer agreement
Moderate agreement for mrT (Quadratic Kappa ¼ 0.5 SE ¼ 0.27).
Poor agreement for length change/modified RECIST (Quadratic Kappa ¼ 0.03 SE ¼ 0.16).
Moderate agreement for mrEMVI (Kappa ¼ 0.59 SE ¼ 0.15).
Good agreement for mrTRG agreement (Kappa ¼ 0.76
No patients were excluded from the trial after central radiology review.
Raw data in supplementary Tables S10-S13, available at Annals of Oncology online.
Discussion
This analysis aimed to determine the prognostic significance of MRI and pathology findings in rectal cancer patients receiving systemic neoadjuvant chemotherapy with high risk of metastatic disease but a low risk of local recurrence (MRI T3, mrCRM clear).
Of the variables assessed baseline MRI assessment of EMVI status appears the most important factor that predicts both DFS and cumulative incidence of recurrence. Three-year DFS for mrEMVI positive patients was 44% versus 96% for mrEMVI negative patients (P ¼ 0.0001). Three-year cumulative incidence of recurrence for mrEMVI positive patients was 44% versus 4% for mrEMVI negative patients (P ¼ 0.0019).
These results are in line with the Panex [16] , pooled analysis of two trials investigating neoadjuvant CAPOX followed by chemoradiotherapy. The analysis included 269 patients, 71% were mrEMVI positive at baseline. A 5-year local progression free survival (PFS), distant PFS, PFS and overall survival were 94%, 79%, 70% and 73%, respectively. Baseline mrEMVI was a significant independent prognostic value in multivariate analyses for distant PFS, HR 2.07, P ¼ 0.03. These findings justify the need for improvement treatment and surveillance of mrEMVI positive patients.
Although baseline MRI and pathological nodal status were significant on univariate analysis, nodal status was not significant on multivariate analysis. Therefore having policy of treating patients according to MRI nodal status rather than mrEMVI status may result in suboptimal patient stratification.
In previous trials reversion from mrEMVI positive to post-chemoradiation mrEMVI negative was 47% (89/188) [17] , with patients rendered mrEMVI negative post-CRT showing a significant survival advantage versus those with persistent mrEMVI 79.2% versus 42.7% [17] . In contrast, systemic chemotherapy used in this trial has shown a higher mrEMVI reversion rate of 91% (23 patients were EMVI positive on baseline MRI, with 2 remaining mrEMVI positive post-chemotherapy). This a The two patients who were ymrEMVI positive were also events (recurrences), thus odds ratio cannot be calculated. high reversion rate did not translate to improvement in DFSwith baseline mrEMVI remaining a poor prognostic factor despite treatment. We can hypothesize this maybe because radiation is more effective in eradicating pathways of vascular spread in the pelvis. A future randomized controlled trial may need to stratify for mrEMVI and consider further therapy intensification for such patients (such as chemoradiation).
On the other hand, in this trial those patients with a baseline MR T3a/b tumour, mrEMVI negative, regardless of nodal status have a very low rate of both distant failure and local recurrence. For many of these patients, primary TME surgery is undertaken with similar results [3] .
A limitation of the study is the relatively small sample size which has produced relatively wide confidence intervals and significant relationships between different imaging parameters (sup  plementary Tables S3-S9 , available at Annals of Oncology online). Despite this, the lower limits of the confidence interval for significant factors was >1. While a greater sample size would undoubtedly narrow the limits this would not alter the conclusions. The sample size of 46 compares favourably with similar publications to date [7, 18] though none so far have examined the prognostic importance of MRI imaging characteristics (which unlike these recent trials was mandatory in the GEMCAD study).
Bevacizumab was included in the chemotherapy regime due to its VEG-F inhibitor effects potentially acting on tumour in vessels.
The results of this trial cannot be generalized to neoadjuvant chemotherapy regimens which do not employ Bevacizumb. Other neoadjuvant regimes are being investigated, TRIGGER is an international phase III study where patients will be stratified by baseline mrEMVI status with the use of neoadjuvant CAPOX/FOLFOX verses the standard of care. Clinical TrialsID:NCT02704520.
The Mandard [19] and Dworak [10] are commonly used to define pathological TRG. While the extremes of both classifications have identical definitions there are differences in the subdivisions. For example, Mandard TRG2 is classified as a good response, whereas many of those patients would be classified as a poor response in the Dworak classification. The superiority of Mandard over Dworak in predicting outcomes has been demonstrated by Santos et al. [20] . This study shows a lack of prognostic relevance of pathological Dworak TRG compared with Mandard based mrTRG (which was significant on univariate analysis for DFS and cumulative incidence of recurrence). This may be due to a greater number of poor responders being identified using the Dworak system.
Conclusion
The study used MRI to stratify patients for treatment, enabling identification of good and poor prognostic subgroups of T3 tumours. The poor prognostic group identified using baseline EMVI status comprises half the patients with stage 2 or 3 disease and such patients have the highest risk of distant failure. These results warrant future studies focused in these patients and should include intensification of preoperative treatment if survival improvements are to be achieved.
